The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan

Abstract

Abstract The article deals with the changes in diagnosis and treatment of early and advanced HER2-positive breast cancer (BC) in Turkmenistan during 2010-2018. Early BC detection programme started in Turkmenistan in the year 2010 and the percentage of stage I-II BC detection in the country increased by 8.8% and reached 69.6% in 2017. Automated HER2-testing method in diagnostic breast tumors was carried out in December 2016; the number of immunohistochemical studies was increased in 2 times from December 2016 to December 2017 and the percentage of HER2 status assessment in patients with newly diagnosed disease reached 99%. The central programme of targeted therapy for HER2-positive BC with trastuzumab and pertuzumab, first in patients with advanced-stage cancer, and then in patients with early HER2-positive BC started within the country in 2016. The first results of the application of anti-HER2 therapy in Turkmenistan of advanced-stage cancer showed promising results: the higher clinical efficacy and favourable safety profile in the treatment. The first results of anti-HER2 blockade in the neoadjuvant chemotherapy confirmed the high percentage of the complete morphological regression in HER2-positive BC, and gave us hope for the future associated with higher survival rates.

Keywords

• her2-positive breast cancer
• the programme of early diagnosis and treatment of her2-positive breast cancer in turkmenistan
• her2 testing results in turkmenistan
• neoadjuvant systemic therapy
• complete morphological response
• 10.26442/1815-1434_2018.2.42-44